Tag: Cerus Endovascular

Stryker completes acquisition of Cerus Endovascular

KALAMAZOO, Michigan, USA, May 2, 2023 /PRNewswire/ — Stryker (NYSE:SYK), one of the world’s leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular’s CE Marked products, […]

Cerus Endovascular Names Stephen Griffin as Chief Executive Officer

FREMONT, Calif. and OXFORD, United Kingdom, July 12, 2022 /PRNewswire/ — Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today the appointment of Stephen Griffin, Ph.D. to Chief Executive Officer, effective immediately. Dr. Griffin has been with the company since 2014 and was appointed President in 2018. He was critical in assembling the current Cerus Endovascular team […]

Cerus Endovascular Receives U.S. Food and Drug Administration 510(k) Clearance of its 027 Micro-catheter

–  Company Announces Expansion of its Contour Neurovascular System™ Platform – FREMONT, Calif. and OXFORD, England, March 23, 2022 /PRNewswire/ — Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 027 micro-catheters, available in two lengths, expanding its product portfolio which includes […]

Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™

Patient Enrollment to Begin Within Three Months FREMONT, Calif. and OXFORD, United Kingdom, April 21, 2021 /PRNewswire/ — Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the […]

Cerus Endovascular Announces the First Ever Robotic Assist Intracranial Implant of its Contour Intrasaccular Device

Groundbreaking Aneurysm Procedure Completed in 28 Minutes FREMONT, Calif. and OXFORD, United Kingdom, Dec. 17, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced the first ever robotically assisted intracranial implant of its Contour intrasaccular device. The groundbreaking procedure was completed at the King Edward Memorial Hospital, Mumbai, by renowned neurosurgeon, Dr. Nitin Dange and was performed on a Middle […]

Cerus Endovascular and Balt Enter Strategic Distribution Agreement for Innovative Neurovascular Devices to Treat a Range of Intracranial Aneurysms

Balt to Commercialize Cerus Endovascular’s Contour Neurovascular System™ and Neqstent Coil Assisted Flow Diverter in Germany FREMONT, Calif. and OXFORD, United Kingdom and MONTMORENCY, France, Aug. 4, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company and AB Medica Deutschland Verwaltungs GmbH, a wholly owned subsidiary of Balt, today announced that they have entered into a strategic distribution agreement providing […]

Cerus Endovascular Receives CE Mark Approval for its 021 Contour Neurovascular System™

Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020 FREMONT, Calif. and OXFORD, England, April 29, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System™, compatible with smaller commercially available 021 microcatheters for the treatment of […]

Cerus Endovascular Receives CE Mark Approvals for its Neqstent™ Coil Assisted Flow Diverter Designed to Treat Intracranial Aneurysms

Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020 FREMONT, Calif. and OXFORD, United Kingdom, April 22, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its Neqstent™  Coil Assisted Flow Diverter device, designed to treat intracranial aneurysms. Neqstent™ is designed to […]

Cerus Endovascular Receives CE Mark Approval for its Contour Neurovascular System™, Designed to Treat Intracranial Aneurysms

Commercial Sales Across European Union Expected to Begin in Second Quarter of 2020 FREMONT, Calif. and OXFORD, England, Feb. 18, 2020 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its lead product, the Contour Neurovascular System™, for the treatment of intracranial aneurysms. The Contour Neurovascular […]

Cerus Endovascular Promotes Stephen Griffin, PhD, to President

FREMONT, Calif. and OXFORD, England, May 11, 2018 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysm, today announced the promotion of Stephen Griffin, PhD, to president of the company, […]